ORIC — Oric Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1796280 ·
Last close
$8.27
Market Cap
$856.09M
52W High
$13.04
52W Low
$7.23
ADV30
1,642,057
Next earnings
2026-05-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -39,619,000 | -35,767,000 | 436,762,000 | 56,396,000 | 21,205,000 |
| Dec 2025 | 0 | — | -34,551,000 | -30,505,000 | 408,890,000 | 45,669,000 | 24,528,000 |
| Sep 2025 | 0 | — | -36,671,000 | -32,587,000 | 431,192,000 | 49,668,000 | 24,273,000 |
| Jun 2025 | 0 | — | -39,064,000 | -36,355,000 | 346,857,000 | 75,864,000 | 22,862,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-110,875,000
Investing CF
$-188,456,000
Financing CF
$306,393,000
CapEx
$-327,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-728,009,000
Inventory
—
Receivables
—
ST Investments
$225,536,000
EBIT TTM
$-149,905,000
Pretax Income TTM
$-135,214,000
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -143,004,000 | -129,468,000 | 408,890,000 | 24,528,000 | — | -110,970,000 |
| Dec 2024 | 0 | -142,895,000 | -127,847,000 | 274,142,000 | 31,020,000 | — | -112,662,000 |
| Dec 2023 | 0 | -110,780,000 | -100,697,000 | 252,007,000 | 27,919,000 | — | -85,688,000 |
| Dec 2022 | 0 | -86,767,000 | -89,122,000 | 247,178,000 | 24,827,000 | — | -75,143,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.57
Max Pain — expiry 2027-01-15
max pain strike: $7.00 · spot: $8.40 · call oi: 4,323 · put oi: 10
Expected Move to 2027-01-15:
±$8.15
(97.02%) —
implied range
$0.25 –
$16.55
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TBPH | Theravance Biopharma, Inc. | $857.84M | $16.64 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $852.86M | $1.92 | — |
| OLMA | Olema Pharmaceuticals, Inc. | $862.12M | $9.87 | — |
| ETON | Eton Pharmaceuticals, Inc. | $865.32M | $31.59 | — |
| ABUS | Arbutus Biopharma Corp | $841.51M | $4.26 | — |
News headlines (Yahoo Finance, 1h cache)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 20:30 · Yahoo
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-27 20:05 · Yahoo
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
2026-05-17 13:23 · Yahoo
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
2026-05-04 20:05 · Yahoo
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Researc
2026-04-17 20:05 · Yahoo
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data
2026-04-06 09:08 · Yahoo
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
2026-04-02 12:20 · Yahoo
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3
2026-04-02 08:13 · Yahoo
Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges
2026-04-01 20:16 · Yahoo
Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened
2026-04-01 13:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.